Annovis Bio
ANVS
7 hedge funds and large institutions have $581K invested in Annovis Bio in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2.82% more ownership
Funds ownership: 0% → 2.82% (+2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$708K |
| 2 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
+$136K |
| 3 |
CC
Cannell & Co
New York
|
+$49.2K |
| 4 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
+$49.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$6.03K |
Top Sellers
ANVS Hedge Fund Activity: Q1 2020 in Review
7 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q1 2020, worth a combined $581K.
Buyers outnumbered sellers: 7 funds opened new ANVS positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Worth Venture Partners, opening a new position worth an estimated $708K.
- 7 institutional investors held Annovis Bio (ANVS) as of Q1 2020, up from 0 in Q4 2019.
- Funds reported $581K of Annovis Bio stock for Q1 2020.
- 7 funds opened new Annovis Bio positions in Q1 2020 and 0 closed out, a net change of +7 holders.
- The largest Annovis Bio buyer in Q1 2020 was Worth Venture Partners, an estimated $708K added.
Based on aggregated 13F filings for Q1 2020.